For the second quarter of 2026, consensus estimates place Novanta’s revenue at $262.1 million and adjusted EPS at $0.83, with the current stock price of $147.73 sitting well below the $175.00 average analyst target.
Investors are primarily watching for the initial impact of the recently finalized $1.2 billion acquisition of Riverpoint Medical on the company's recurring medical consumables revenue and healthcare market exposure.
Management has guided for organic revenue growth between 6% and 8% for Q2 2026 as demand recovers in the semiconductor and industrial sectors, alongside accelerating sales in AI data center infrastructure. Market participants are also looking for gross margin improvements following the implementation of price surcharges aimed at offsetting persistent freight and tariff cost inflation.